idiopathic pulmonary fibrosis

balloon missed target pop arrows miss failure
Pharma

Syndax ends IPF development after phase 2 disappointment

In topline phase 2 results, Syndax’s Niktimvo did not slow worsening lung function in IPF patients compared to placebo.
Donavyn Coffey Oct 13, 2026 11:25am
Lung
Favicon Fierce Biotech

Avalyn aims for $182M IPO to fund ph. 3 trials of lung drugs

Apr 24, 2026 7:08am
IPO initial public offering
Favicon Fierce Biotech

Avalyn plans IPO to fund ph. 3 trials of inhaled lung drugs

Apr 9, 2026 4:13am
Sketch of lungs

United's Tyvaso backs up case for IPF expansion with ph. 3 win

Mar 30, 2026 3:06pm
Boehringer Ingelheim Boehringer

Boehringer touts promising launches of Hernexeos, Jascayd

Mar 25, 2026 10:57am
Boehringer Ingelheim Boehringer

BI's Jascayd quickly expands lung disease reach with new FDA nod

Dec 22, 2025 12:02pm